Pfenex Stock Price, News & Analysis (NYSEAMERICAN:PFNX)

$2.14 -0.09 (-4.04 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$2.23
Today's Range$2.10 - $2.26
52-Week Range$2.07 - $9.79
Volume60,949 shs
Average Volume115,202 shs
Market Capitalization$49.22 million
P/E RatioN/A
Dividend YieldN/A


Pfenex logoPfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($1.78)
Net IncomeN/A
Net Margins-175.52%
Return on Equity-63.57%
Return on Assets-46.31%


Outstanding Shares23,550,000

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) issued its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.17. The biotechnology company earned $5.02 million during the quarter, compared to the consensus estimate of $3.30 million. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. The business's quarterly revenue was down 89.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 EPS. View Pfenex's Earnings History.

When will Pfenex make its next earnings announcement?

Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Pfenex.

Where is Pfenex's stock going? Where will Pfenex's stock price be in 2017?

1 Wall Street analysts have issued 1 year target prices for Pfenex's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Pfenex's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Pfenex.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:

  • Evert B. Schimmelpennink, President, Chief Executive Officer, Acting Principal Financial Officer, Secretary, Director
  • Patricia Lady CPA, Chief Accounting Officer
  • Hubert C. Chen M.D., Chief Medical Officer
  • Patrick K. Lucy, Chief Business Officer
  • Robin D. Campbell Ph.D., Independent Director
  • Dennis M. Fenton Ph.D., Independent Director
  • Phillip M. Schneider, Independent Director
  • John M. Taylor III, Independent Director

Who owns Pfenex stock?

Pfenex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SANDERS MORRIS HARRIS LLC (5.00%), Sanders Morris Harris LLC (4.24%), Dimensional Fund Advisors LP (1.29%), C WorldWide Group Holding A S (1.15%) and OxFORD Asset Management LLP (0.69%). Company insiders that own Pfenex stock include Chemical Co /De/ Dow, Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Who sold Pfenex stock? Who is selling Pfenex stock?

Pfenex's stock was sold by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP. Company insiders that have sold Pfenex company stock in the last year include Patricia Lady and Signet Healthcare Partners Acc. View Insider Buying and Selling for Pfenex.

Who bought Pfenex stock? Who is buying Pfenex stock?

Pfenex's stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Dimensional Fund Advisors LP and C WorldWide Group Holding A S. View Insider Buying and Selling for Pfenex.

How do I buy Pfenex stock?

Shares of Pfenex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of Pfenex stock can currently be purchased for approximately $2.14.

How big of a company is Pfenex?

Pfenex has a market capitalization of $49.22 million.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.

MarketBeat Community Rating for Pfenex (PFNX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  193
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfenex (NYSEAMERICAN:PFNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$13.33$16.00$18.00
Price Target Upside: 308.81% upside319.29% upside357.14% upside71.76% upside

Pfenex (NYSEAMERICAN:PFNX) Consensus Price Target History

Price Target History for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN:PFNX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
11/10/2017JMP SecuritiesLower Price TargetPositive -> Outperform$21.00 -> $8.00View Rating Details
9/8/2017William BlairReiterated RatingOurperformView Rating Details
8/9/2016MizuhoLower Price TargetBuy$22.00 -> $18.00View Rating Details
5/24/2016BarclaysLower Price TargetOverweight$28.00 -> $14.00View Rating Details
(Data available from 12/15/2015 forward)


Pfenex (NYSEAMERICAN:PFNX) Earnings History and Estimates Chart

Earnings by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN PFNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.54)($0.37)$3.30 million$5.02 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.52)$3.10 million$3.03 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.57)($0.43)$2.50 million$2.80 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.66)($0.45)$2.50 million$5.47 millionViewN/AView Earnings Details
11/9/2016Q316($0.56)$1.46$3.18 million$48.82 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.43)$2.55 million$3.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.45)($0.35)$2.35 million$2.76 millionViewN/AView Earnings Details
3/10/2016Q415($0.59)($0.37)$2.56 million$3.30 millionViewListenView Earnings Details
11/13/2015Q315($0.46)($0.33)$2.05 million$2.06 millionViewListenView Earnings Details
8/13/2015Q215($0.39)($0.27)$2.07 million$2.30 millionViewListenView Earnings Details
5/14/2015Q115($0.24)($0.29)$2.10 million$2.00 millionViewListenView Earnings Details
3/16/2015Q4($0.20)($0.18)$2.05 million$2.02 millionViewN/AView Earnings Details
11/13/2014Q3($0.25)($0.16)$2.13 million$2.80 millionViewN/AView Earnings Details
8/29/2014($0.15)($1.67)$1.75 million$3.27 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Pfenex (NYSEAMERICAN:PFNX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Pfenex (NYSEAMERICAN:PFNX)

No dividend announcements for this company have been tracked by

Insider Trades

Pfenex (NYSEAMERICAN PFNX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Pfenex (NYSEAMERICAN:PFNX)
Insider Trades by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN PFNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Jason Grenfell-GardnerDirectorBuy10,000$4.51$45,100.00View SEC Filing  
5/16/2017Patricia LadyInsiderSell2,000$4.78$9,560.00View SEC Filing  
1/6/2017Signet Healthcare Partners AccMajor ShareholderSell400$9.50$3,800.00View SEC Filing  
1/5/2017Signet Healthcare Partners AccMajor ShareholderSell7,710$9.50$73,245.00View SEC Filing  
12/29/2016Signet Healthcare Partners AccMajor ShareholderSell24,104$9.66$232,844.64View SEC Filing  
12/27/2016Signet Healthcare Partners AccMajor ShareholderSell104,600$9.58$1,002,068.00View SEC Filing  
12/22/2016Signet Healthcare Partners AccMajor ShareholderSell10,896$9.61$104,710.56View SEC Filing  
11/21/2016Patricia LadyInsiderSell2,000$9.87$19,740.00View SEC Filing  
11/15/2016Patrick K. LucyInsiderSell5,000$10.04$50,200.00View SEC Filing  
8/18/2016Patricia LadyInsiderSell2,000$9.42$18,840.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
12/15/2015Chemical Co /De/ DowMajor ShareholderSell600,000$11.75$7,050,000.00View SEC Filing  
12/3/2015Patrick K LucyInsiderSell1,500$14.15$21,225.00View SEC Filing  
12/1/2015Bertrand C. LiangCEOSell5,000$14.88$74,400.00View SEC Filing  
12/1/2015Henry W Jr. TalbotVPSell2,000$15.08$30,160.00View SEC Filing  
11/18/2015Patricia LadyCAOSell2,000$14.05$28,100.00View SEC Filing  
11/4/2015Patrick K. LucyinsiderSell1,500$17.54$26,310.00View SEC Filing  
11/2/2015Bertrand C LiangCEOSell5,000$18.01$90,050.00View SEC Filing  
10/2/2015Patrick K LucyInsiderSell1,500$14.98$22,470.00View SEC Filing  
10/1/2015Bertrand C LiangCEOSell5,000$14.78$73,900.00View SEC Filing  
9/3/2015Patricia LadyCAOSell2,000$20.48$40,960.00View SEC Filing  
9/3/2015Patrick K LucyInsiderSell1,500$20.91$31,365.00View SEC Filing  
9/1/2015Bertrand C. LiangCEOSell5,000$21.02$105,100.00View SEC Filing  
7/6/2015Patrick K LucyInsiderSell1,500$19.17$28,755.00View SEC Filing  
7/1/2015Bertrand C LiangCEOSell5,000$19.63$98,150.00View SEC Filing  
6/3/2015Patrick K LucyInsiderSell1,500$20.08$30,120.00View SEC Filing  
6/1/2015Bertrand C LiangCEOSell5,000$18.70$93,500.00View SEC Filing  
5/4/2015Patrick K LucyInsiderSell1,500$13.25$19,875.00View SEC Filing  
5/1/2015Bertrand C LiangCEOSell5,000$13.49$67,450.00View SEC Filing  
4/29/2015Chemical Co /De/ DowMajor ShareholderSell2,232,233$14.57$32,523,634.81View SEC Filing  
4/29/2015James C GaleDirectorSell1,907,767$14.57$27,796,165.19View SEC Filing  
4/2/2015Patrick K LucyInsiderSell1,500$17.62$26,430.00View SEC Filing  
4/1/2015Bertrand C LiangCEOSell5,000$15.27$76,350.00View SEC Filing  
3/4/2015Patrick K LucyInsiderSell1,500$14.36$21,540.00View SEC Filing  
7/29/2014Signet Healthcare Partners AccMajor ShareholderSell380,867$0.31$118,068.77View SEC Filing  
(Data available from 1/1/2013 forward)


Pfenex (NYSEAMERICAN PFNX) News Headlines

Zacks Investment Research Downgrades Pfenex Inc. (PFNX) to HoldZacks Investment Research Downgrades Pfenex Inc. (PFNX) to Hold - November 19 at 11:36 PM

SEC Filings


This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Pfenex (NYSEAMERICAN PFNX) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.